StockMacro
Menu

Ginkgo Bioworks

$7.46 -14% in 6 monthsMarket cap $483.5M

DNA on XNYS, Health Care, Ginkgo Bioworks Holdings, Inc., job postings

Measures activity, not value. Not investment advice.

Quarterly revenue fell 29% to $27.7M and shares dropped 25% in a month.

  • BadFederal contracts and grants fell to $27.1M from $68.5M
  • BadRevenue for the last 12 months down 33% to $100.7M

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering engaged in providing biological R&D services for customers across a range of industries and Biosecurity that provides services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.

Industry
Biological products, (no diagnostic substances) (Health Care)
Employees
485
Website
ginkgobioworks.com
Listed
NYSE, US
Last results
5 Nov 2026
Next results
expected around 25 Feb 2027 (an estimate: a year ago it reported on 26 Feb 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $27.7M, net loss $41.0M.
Quarter to 31 Dec 2021: revenue $148.5M, net income -$1.6BQuarter to 31 Dec 2021: revenue $148.5M, net income -$1.6BQuarter to 31 Mar 2022: revenue $168.4M, net income -$590.5MQuarter to 31 Mar 2022: revenue $168.4M, net income -$590.5MQuarter to 30 Jun 2022: revenue $144.6M, net income -$668.8MQuarter to 30 Jun 2022: revenue $144.6M, net income -$668.8MQuarter to 30 Sep 2022: revenue $66.4M, net income -$669.1MQuarter to 30 Sep 2022: revenue $66.4M, net income -$669.1MQuarter to 31 Dec 2022: revenue $98.3M, net income -$176.5MQuarter to 31 Dec 2022: revenue $98.3M, net income -$176.5MQuarter to 31 Mar 2023: revenue $80.7M, net income -$205.0MQuarter to 31 Mar 2023: revenue $80.7M, net income -$205.0MQuarter to 30 Jun 2023: revenue $80.6M, net income -$173.3MQuarter to 30 Jun 2023: revenue $80.6M, net income -$173.3MQuarter to 30 Sep 2023: revenue $55.4M, net income -$302.9MQuarter to 30 Sep 2023: revenue $55.4M, net income -$302.9MQuarter to 31 Dec 2023: revenue $34.8M, net income -$211.7MQuarter to 31 Dec 2023: revenue $34.8M, net income -$211.7MQuarter to 31 Mar 2024: revenue $37.9M, net income -$165.9MQuarter to 31 Mar 2024: revenue $37.9M, net income -$165.9MQuarter to 30 Jun 2024: revenue $56.2M, net income -$217.2MQuarter to 30 Jun 2024: revenue $56.2M, net income -$217.2MQuarter to 30 Sep 2024: revenue $89.0M, net income -$56.4MQuarter to 30 Sep 2024: revenue $89.0M, net income -$56.4MQuarter to 31 Dec 2024: revenue $43.8M, net income -$107.5MQuarter to 31 Dec 2024: revenue $43.8M, net income -$107.5MQuarter to 31 Mar 2025: revenue $48.3M, net income -$91.0MQuarter to 31 Mar 2025: revenue $48.3M, net income -$91.0MQuarter to 30 Jun 2025: revenue $49.6M, net income -$60.3MQuarter to 30 Jun 2025: revenue $49.6M, net income -$60.3MQuarter to 30 Sep 2025: revenue $38.8M, net income -$80.8MQuarter to 30 Sep 2025: revenue $38.8M, net income -$80.8MQuarter to 31 Dec 2025: revenue $33.4M, net income -$80.8MQuarter to 31 Dec 2025: revenue $33.4M, net income -$80.8MQuarter to 31 Mar 2026: revenue $19.5M, net income -$82.6MQuarter to 31 Mar 2026: revenue $19.5M, net income -$82.6MQuarter to 30 Jun 2026: revenue $20.2M, net income -$46.7MQuarter to 30 Jun 2026: revenue $20.2M, net income -$46.7MQuarter to 30 Sep 2026: revenue $27.7M, net income -$41.0MQuarter to 30 Sep 2026: revenue $27.7M, net income -$41.0M
31 Dec 2021RevenueNet incomeNet losstallest bar $1.6B30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$27.7M-$41.0M
30 Jun 2026$20.2M-$46.7M
31 Mar 2026$19.5M-$82.6M
31 Dec 2025$33.4M-$80.8M
30 Sep 2025$38.8M-$80.8M
30 Jun 2025$49.6M-$60.3M
31 Mar 2025$48.3M-$91.0M
31 Dec 2024$43.8M-$107.5M
30 Sep 2024$89.0M-$56.4M
30 Jun 2024$56.2M-$217.2M
31 Mar 2024$37.9M-$165.9M
31 Dec 2023$34.8M-$211.7M
30 Sep 2023$55.4M-$302.9M
30 Jun 2023$80.6M-$173.3M
31 Mar 2023$80.7M-$205.0M
31 Dec 2022$98.3M-$176.5M
30 Sep 2022$66.4M-$669.1M
30 Jun 2022$144.6M-$668.8M
31 Mar 2022$168.4M-$590.5M
31 Dec 2021$148.5M-$1.6B
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $100.7M $150.6M
Revenue growthRevenue of the last 12 months compared with the 12 months before. -33% +8.2%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$251.0M -$339.5M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). – –
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. – – 70.4%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. -243% -216% -98.6%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. -249% -225% -47.8%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. -52.7% -58.2%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. – –
CashCash, cash equivalents and short-term investments on the latest balance sheet. $84.5M $495.5M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $0 $0
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). -$84.5M (net cash) -$495.5M
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 0.0 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. –
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 21.6
P/SPrice to sales: market cap divided by revenue of the last 12 months. 4.8 8.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. 4.0 6.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 1.2 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
Ginkgo BioworksDNA (this company) $483.5Mloss4.8-33%-249%
Sana BiotechnologySANA $476.4Mloss–––
RegenxbioRGNX $473.4Mloss3.1-4.6%-114%
Fennec PharmaceuticalsFENC $462.1M2287.0+71%3.1%
Electra TherapeuticsETRA $509.8M––––
IRulya TherapeuticsIRLA $432.4Mloss–––

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

-$1.4M

bought $0, sold $1.4M

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

-1.6%

180 13F filers vs 183

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

–

No 13F holdings or share count.

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

–

9.5M shares sold short (30 Oct 2026); no share count in the company's filings in our data

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

3.9

9.5M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

+14%

8.3M shares sold short in the report before, 9.5M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

64%

64% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 57%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

17

Tracked since 20 Nov 2026

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

Tracking started 20 Nov 2026; the change shows after 30 days.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

–

No data for this company

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

-29%

$27.7M vs $38.8M (quarter ended 30 Sep 2026)

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

–

No data for this company

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

$27.1M

the 12 months before: $68.5M

Lobbying What the company reported spending on federal lobbying over the last four quarters.

$270K

4 quarters, $

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

19

19 articles in the last 7 days; its usual week has 2 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

9.5×

19 articles in the last 7 days; its usual week has 2.

Unusual now sharp changes in the last 90 days, compared with its own past

  • Lobbying spend $120K, 4.0× its usual level

Price $7.46 on 20 Nov 2026, -4.6% over 12 months (12-month range $5.48 to $14.98)

  • Sharp change
  • 8-K and other filings
  • WARN layoff notice
  • Lobbying filing
Insider net buying (open market). Insiders sold a net $5.0M in the last 12 months (the 12 months before: -$406K).
H-1B/E-3 applications certified. H-1B/E-3 applications certified: 1 published in the last 12 months (none in the 12 months before).
Revenue per quarter. Revenue $27.7M in the latest quarter, -29% on a year earlier.
Capital spending per quarter. Capital spending $2.0M in the latest quarter.
Institutional holders (13F filers). 180 13F filers reported holding it in the latest 13F quarter, +12% on a year earlier.
Federal obligations. Federal obligations: $29.6M published in the last 12 months, +476% on the 12 months before.
Lobbying spend. Lobbying spend: $270K published in the last 12 months, +2600% on the 12 months before.
Workers in WARN layoff notices. Workers in WARN layoff notices: 0 published in the last 12 months.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
21 Nov 2026Sharp changeLobbying spend jump: lobbying spend jump, 120K vs usual 30K (2026-09-30)
7 Apr 2026Sharp changeFederal obligations jump: federal obligations jump, 21.0M vs usual 5,000 in the same month of earlier years (2026-03-01..2026-03-31)
7 Apr 20268-K and other filingsCompleted an acquisition or asset sale
23 Dec 20258-K and other filingsDirector or officer change
23 Dec 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
11 Dec 2025Lobbying filingnew lobbying registration (CROSSROADS STRATEGIES, LLC)
21 May 20258-K and other filingsDirector or officer change
21 May 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
11 Feb 2025Sharp changeFederal obligations jump: federal obligations jump, 54.2M vs usual 672K in the same month of earlier years (2025-01-01..2025-01-31); 2.8x the same month a year earlier
21 Jan 2025Lobbying filinglobbying engagement terminated (KYLE HOUSE GROUP)
12 Nov 20248-K and other filingsDirector or officer change
12 Nov 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
8 Oct 2024Sharp changeFederal obligations jump: federal obligations jump, 10.2M vs usual 887K in the same month of earlier years (2024-09-01..2024-09-30); 5.8x the same month a year earlier
10 Sep 2024Sharp changeFederal obligations jump: federal obligations jump, 54.5M vs usual 16.0M in the same month of earlier years (2024-08-01..2024-08-31); 3.4x the same month a year earlier
4 Sep 20248-K and other filingsDelisting notice or listing transfer
18 Jun 2024WARN layoff noticeGinkgo Bioworks, Inc., 158 workers, Boston, Cambridge, MA
18 Jun 2024Sharp changeWARN layoff notice: wARN layoff notice (1 event(s) in 30 days, workers total 158)
13 May 20248-K and other filingsDelisting notice or listing transfer
9 May 20248-K and other filingsRestructuring costs announced
14 Mar 20248-K and other filingsChanged its auditor
6 Feb 2024Sharp changeFederal obligations jump: federal obligations jump, 19.0M vs usual 336K in the same month of earlier years (2024-01-01..2024-01-31)
18 Oct 2023Lobbying filinglobbying engagement terminated (HORIZONS GLOBAL SOLUTIONS LLC)
21 Aug 2023Lobbying filinglobbying engagement terminated (GOVERNMENT SOLUTIONS LLC)
21 Aug 2023Sharp changeLobbying on a new issue: lobbying on a new issue: FOR (2023-06-30)
25 Jul 2023Sharp changeLobbying spend jump: lobbying spend jump, 180K vs usual 90K (2023-03-31); 2.0x the same period a year earlier
16 Jul 2023Lobbying filinglobbying engagement terminated (FORBES-TATE)
5 May 20238-K and other filingsDirector or officer change
5 May 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
14 Apr 2023Lobbying filingnew lobbying registration (KYLE HOUSE GROUP)
3 Apr 2023Lobbying filingnew lobbying registration (HORIZONS GLOBAL SOLUTIONS LLC)
17 Mar 2023Sharp changeFirst award from a new federal agency: first award from a new federal agency (Department of Defense): GINKGO BIOWORKS, INC.: new Department of Defense contract W911NF23C0002 ($1,500,000)
2 Mar 2023Lobbying filingnew lobbying registration (CORNERSTONE GOVERNMENT AFFAIRS, INC.)
1 Mar 20238-K and other filingsReport will be filed late
19 Oct 20228-K and other filingsCompleted an acquisition or asset sale
17 Oct 2022Sharp changeLobbying on a new issue: lobbying on a new issue: AGR (2022-06-30)
27 Sep 20228-K and other filingsRegistered new securities for sale (S-1)
7 Sep 20228-K and other filingsRegistered new securities for sale (S-1)
22 Aug 2022Sharp changeFirst federal award: first federal award: GINKGO BIOWORKS, INC.: new Department of Health and Human Services contract 75D30122C14933 ($15,979,933)
4 Aug 20228-K and other filingsDirector or officer change
4 Aug 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
12 Apr 20228-K and other filingsRegistered new securities for sale (S-1)
5 Apr 20228-K and other filingsRegistered new securities for sale (S-1)
24 Nov 20218-K and other filingsRegistered new securities for sale (S-1)
Insider net buying (open market)
Month from 1 Oct 2022: -$44.5M published
Month from 1 Nov 2022: -$35.3M published
Month from 1 Dec 2022: -$21.9M published
Month from 1 Jan 2023: -$21.8M published
Month from 1 Feb 2023: -$14.2M published
Month from 1 Mar 2023: -$1.9M published
Month from 1 Apr 2023: -$2.3M published
Month from 1 May 2023: -$1.3M published
Month from 1 Jun 2023: -$2.6M published
Month from 1 Jul 2023: -$3.7M published
Month from 1 Aug 2023: -$2.7M published
Month from 1 Sep 2023: -$3.6M published
Month from 1 Oct 2023: -$2.3M published
Month from 1 Nov 2023: -$2.1M published
Month from 1 Dec 2023: -$2.2M published
Month from 1 Jan 2024: -$381K published
Month from 1 Feb 2024: -$48K published
Month from 1 Mar 2024: -$49K published
Month from 1 Apr 2024: -$54K published
Month from 1 May 2024: -$1.2M published
Month from 1 Jun 2024: -$34K published
Month from 1 Jul 2024: -$21K published
Month from 1 Aug 2024: -$24K published
Month from 1 Sep 2024: -$9K published
Month from 1 Oct 2024: -$13K published
Month from 1 Nov 2024: -$13K published
Month from 1 Dec 2024: -$10K published
Month from 1 Jan 2025: -$11K published
Month from 1 Feb 2025: -$15K published
Month from 1 Mar 2025: -$9K published
Month from 1 Apr 2025: -$16K published
Month from 1 May 2025: -$8K published
Month from 1 Jul 2025: -$11K published
Month from 1 Aug 2025: -$4K published
Month from 1 Sep 2025: -$220K published
Month from 1 Oct 2025: -$102K published
Month from 1 Dec 2025: -$7K published
Month from 1 Jan 2026: -$9K published
Month from 1 Mar 2026: -$5K published
Month from 1 Apr 2026: -$3.5M published
Month from 1 May 2026: -$3K published
Month from 1 Jul 2026: -$6K published
Month from 1 Aug 2026: -$2K published
Month from 1 Sep 2026: -$35K published
Month from 1 Oct 2026: -$1.3M published
H-1B/E-3 applications certified
Quarter from 1 Oct 2026: 1 published
Revenue per quarter
Quarter ended 31 Dec 2020: $32.1M; public on 30 Mar 2022
Quarter ended 31 Mar 2021: $44.1M; public on 17 May 2022
Quarter ended 30 Jun 2021: $43.6M; public on 16 Aug 2022
Quarter ended 31 Dec 2021: $148.5M, +363% on a year earlier; public on 30 Mar 2022
Quarter ended 31 Mar 2022: $168.4M, +282% on a year earlier; public on 17 May 2022
Quarter ended 30 Jun 2022: $144.6M, +231% on a year earlier; public on 16 Aug 2022
Quarter ended 30 Sep 2022: $66.4M, -14% on a year earlier; public on 15 Nov 2022
Quarter ended 31 Dec 2022: $98.3M, -34% on a year earlier; public on 14 Mar 2023
Quarter ended 31 Mar 2023: $80.7M, -52% on a year earlier; public on 11 May 2023
Quarter ended 30 Jun 2023: $80.6M, -44% on a year earlier; public on 10 Aug 2023
Quarter ended 30 Sep 2023: $55.4M, -17% on a year earlier; public on 9 Nov 2023
Quarter ended 31 Dec 2023: $34.8M, -65% on a year earlier; public on 1 Mar 2024
Quarter ended 31 Mar 2024: $37.9M, -53% on a year earlier; public on 10 May 2024
Quarter ended 30 Jun 2024: $56.2M, -30% on a year earlier; public on 9 Aug 2024
Quarter ended 30 Sep 2024: $89.0M, +61% on a year earlier; public on 13 Nov 2024
Quarter ended 31 Dec 2024: $43.8M, +26% on a year earlier; public on 26 Feb 2025
Quarter ended 31 Mar 2025: $48.3M, +27% on a year earlier; public on 7 May 2025
Quarter ended 30 Jun 2025: $49.6M, -12% on a year earlier; public on 8 Aug 2025
Quarter ended 30 Sep 2025: $38.8M, -56% on a year earlier; public on 7 Nov 2025
Quarter ended 31 Dec 2025: $33.4M, -24% on a year earlier; public on 27 Feb 2026
Quarter ended 31 Mar 2026: $19.5M, -60% on a year earlier; public on 8 May 2026
Quarter ended 30 Jun 2026: $20.2M, -59% on a year earlier; public on 7 Aug 2026
Quarter ended 30 Sep 2026: $27.7M, -29% on a year earlier; public on 10 Nov 2026
Capital spending per quarter
Quarter ended 31 Dec 2020: $19.4M; public on 30 Mar 2022
Quarter ended 31 Mar 2021: $21.9M; public on 17 May 2022
Quarter ended 30 Jun 2021: $24.0M; public on 16 Aug 2022
Quarter ended 31 Dec 2021: $5.1M, -74% on a year earlier; public on 30 Mar 2022
Quarter ended 31 Mar 2022: $3.6M, -84% on a year earlier; public on 17 May 2022
Quarter ended 30 Jun 2022: $9.6M, -60% on a year earlier; public on 16 Aug 2022
Quarter ended 30 Sep 2022: $13.5M, +148% on a year earlier; public on 15 Nov 2022
Quarter ended 31 Dec 2022: $25.6M, +401% on a year earlier; public on 14 Mar 2023
Quarter ended 31 Mar 2023: $19.4M, +443% on a year earlier; public on 11 May 2023
Quarter ended 30 Jun 2023: $13.5M, +41% on a year earlier; public on 10 Aug 2023
Quarter ended 30 Sep 2023: $4.4M, -67% on a year earlier; public on 9 Nov 2023
Quarter ended 31 Dec 2023: $3.4M, -87% on a year earlier; public on 1 Mar 2024
Quarter ended 31 Mar 2024: $6.7M, -65% on a year earlier; public on 10 May 2024
Quarter ended 30 Jun 2024: $27.0M, +100% on a year earlier; public on 9 Aug 2024
Quarter ended 30 Sep 2024: $15.1M, +244% on a year earlier; public on 13 Nov 2024
Quarter ended 31 Dec 2024: $13.7M, +298% on a year earlier; public on 26 Feb 2025
Quarter ended 31 Mar 2025: $7.6M, +14% on a year earlier; public on 7 May 2025
Quarter ended 30 Sep 2025: $0, -100% on a year earlier; public on 7 Nov 2025
Quarter ended 31 Mar 2026: $1.9M, -75% on a year earlier; public on 8 May 2026
Quarter ended 30 Jun 2026: $2.6M; public on 7 Aug 2026
Quarter ended 30 Sep 2026: $2.0M; public on 10 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 151; public on 14 Feb 2022
31 Mar 2022 report: 180; public on 16 May 2022
30 Jun 2022 report: 241; public on 15 Aug 2022
30 Sep 2022 report: 252; public on 14 Nov 2022
31 Dec 2022 report: 294; public on 14 Feb 2023
31 Mar 2023 report: 285; public on 15 May 2023
30 Jun 2023 report: 288; public on 14 Aug 2023
30 Sep 2023 report: 315; public on 14 Nov 2023
31 Dec 2023 report: 318; public on 14 Feb 2024
31 Mar 2024 report: 324; public on 15 May 2024
30 Jun 2024 report: 294; public on 14 Aug 2024
30 Sep 2024 report: 148; public on 14 Nov 2024
31 Dec 2024 report: 163; public on 14 Feb 2025
31 Mar 2025 report: 164; public on 15 May 2025
30 Jun 2025 report: 159; public on 14 Aug 2025
30 Sep 2025 report: 160; public on 14 Nov 2025
31 Dec 2025 report: 172; public on 17 Feb 2026
31 Mar 2026 report: 168; public on 15 May 2026
30 Jun 2026 report: 183; public on 14 Aug 2026
30 Sep 2026 report: 180; public on 16 Nov 2026
Federal obligations
Month from 1 Mar 2022: $0 published
Month from 1 May 2022: $672K published
Month from 1 Jun 2022: $0 published
Month from 1 Aug 2022: $16.0M published
Month from 1 Sep 2022: -$105K published
Month from 1 Nov 2022: $580K published
Month from 1 Jan 2023: $0 published
Month from 1 Mar 2023: $1.5M published
Month from 1 Apr 2023: $0 published
Month from 1 May 2023: $2.1M published
Month from 1 Jun 2023: $2.0M published
Month from 1 Aug 2023: $16.8M published
Month from 1 Sep 2023: $1.8M published
Month from 1 Oct 2023: $953K published
Month from 1 Dec 2023: $0 published
Month from 1 Jan 2024: $19.0M published
Month from 1 Feb 2024: $468K published
Month from 1 Mar 2024: $10K published
Month from 1 Apr 2024: $634K published
Month from 1 May 2024: $1.1M published
Month from 1 Jun 2024: $1.0M published
Month from 1 Aug 2024: $1.9M published
Month from 1 Sep 2024: $56.9M published
Month from 1 Oct 2024: $8.6M published
Month from 1 Dec 2024: -$52.7M published
Month from 1 Jan 2025: $54.2M published
Month from 1 Feb 2025: $500K published
Month from 1 Mar 2025: $124K published
Month from 1 May 2025: $68K published
Month from 1 Jul 2025: -$111K published
Month from 1 Aug 2025: $0 published
Month from 1 Sep 2025: $1.8M published
Month from 1 Oct 2025: $591K published
Month from 1 Nov 2025: $676K published
Month from 1 Dec 2025: $441K published
Month from 1 Jan 2026: $178K published
Month from 1 Apr 2026: $21.0M published
Month from 1 May 2026: $3.2M published
Month from 1 Jun 2026: $0 published
Month from 1 Jul 2026: $200K published
Month from 1 Sep 2026: $1.3M published
Month from 1 Oct 2026: $3.3M published
Lobbying spend
Quarter from 1 Jan 2022: $90K published
Quarter from 1 Apr 2022: $90K published
Quarter from 1 Oct 2022: $180K published
Quarter from 1 Jan 2023: $90K published
Quarter from 1 Apr 2023: $180K published
Quarter from 1 Jul 2023: $90K published
Quarter from 1 Oct 2023: $50K published
Quarter from 1 Jan 2024: $40K published
Quarter from 1 Apr 2024: $30K published
Quarter from 1 Jul 2024: $30K published
Quarter from 1 Apr 2025: $10K published
Quarter from 1 Jan 2026: $30K published
Quarter from 1 Apr 2026: $60K published
Quarter from 1 Jul 2026: $60K published
Quarter from 1 Oct 2026: $120K published
Workers in WARN layoff notices
Month from 1 Jun 2024: 158 published

What is unusual now

  • Made public in the last 90 days: it reported $120K of lobbying spend for the quarter ended 30 Sep 2026, 4.0× its normal quarter.
  • Lobbying spend jump: reported $120K of lobbying spend for the quarter ended 30 Sep 2026, 4.0× its normal quarter Public on 16 Oct 2026.
  • Insider net buying (open market): Insiders sold a net $5.0M in the last 12 months (the 12 months before: -$406K).
  • H-1B/E-3 applications certified: H-1B/E-3 applications certified: 1 published in the last 12 months (none in the 12 months before).

Latest records

The names and amounts behind the totals, newest first

Last 90 days: 7 sales, $1.4M; no purchases. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
21 Oct 2026Steven P. CoenSee remarksSellafter exercising options766$10.14$8KForm 4
21 Oct 2026Barry Canton10% ownerSellafter exercising options41,172$10.14$418KForm 4
21 Oct 2026Reshma P. ShettySee remarksSellafter exercising options41,172$10.14$418KForm 4
21 Oct 2026Jason R KellySee remarksSellafter exercising options45,682$10.14$463KForm 4
7 Oct 2026Steven P. CoenSee remarksSell2,403$15.00$36KForm 4
16 Sep 2026Christian O HenryDirectorSell5,000$7.08$35KForm 4
25 Aug 2026Steven P. CoenSee remarksSellafter exercising options330$6.98$2KForm 4
20 Jul 2026Steven P. CoenSee remarksSellafter exercising options752$7.90$6KForm 4

180 institutions reported shares at the end of Q3 2026; 28 opened a position, 32 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
BlackRock, Inc.4.5M$58.0M+236K+5.5%
Viking Global Investors LP2.9M$37.2M-677K-19%
Erste Asset Management GmbH2.5M$30.3MNo change
Baillie Gifford & Co2.4M$30.7MNo change
Vanguard Capital Management LLC2.1M$27.1M+23K+1.1%
Legal & General Group Plc1.8M$23.3M+143K+8.6%
Anchorage Capital Group, L.L.C.1.7M$22.4MNo change
State Street Corp1.6M$20.1M+96K+6.5%
Vanguard Portfolio Management LLC1.5M$18.7M+520K+55%
Geode Capital Management, LLC1.3M$16.4M+56K+4.6%

Federal contracts

All 6 federal contracts

1 new award in 12 months, $3.2M obligated when signed. New awards only; later changes to an award are not listed.

SignedAgencyAmountWhat forSource
3 May 2026Department of Health and Human ServicesCenters for Disease Control and Prevention$3.2MMETAGENOMIC NEXT-GENERATION SEQUENCING (MNGS)USAspending
17 Jan 2025Department of Health and Human ServicesCenters for Disease Control and Prevention$53.7Mup to $85.7MTRAVELER-BASED GENOMIC SURVEILLANCE PROGRAMUSAspending
6 Sep 2024Department of Health and Human ServicesCenters for Disease Control and Prevention$1.2Mup to $50.2MTEST SURGE AND DATA SHARING MULTIPLE AWARD IDIQUSAspending
26 Aug 2024Department of Health and Human ServicesCenters for Disease Control and Prevention$54.9Mup to $93.7MTRAVELER-BASED GENOMIC SURVEILLANCEUSAspending
15 Dec 2022Department of DefenseDepartment of the Army$4.4Mup to $18.0MDARPA CONTRACT AWARD (BASE) "SUPERB: SYNBIO + UNIVERSAL PURIFICATION OF EXTRACT-DERIVED, RIGHT-ON-TIME BIOLOGICS"USAspending
16 Aug 2022Department of Health and Human ServicesCenters for Disease Control and Prevention$16.0Mup to $61.4MAIRPORT GENOMIC TESTINGUSAspending

Company events

All 37 company events

In 12 months: 1 director or officer change, 1 major agreement, 1 completed deal. Results releases and routine reports are left out.

FiledWhat happenedSource
7 Apr 2026Completed an acquisition or asset sale8-K
26 Feb 2026Signed a major agreement8-K
23 Dec 2025Director or officer change8-K
4 Sep 2025Signed a major agreement8-K
21 May 2025Director or officer change8-K
12 Nov 2024Director or officer change8-K
4 Sep 2024Delisting notice or listing transfer8-K
13 May 2024Delisting notice or listing transfer8-K

17 open postings; careers site tracked since 20 Nov 2026. Most in Software engineering 41%, Research & science 18%, Chip design (ASIC / RTL / verification / physical design) 6%, Embedded & firmware 6%.

PostedJobLocation
2 Nov 2026Mechatronics Engineer IMechanical engineeringBoston, Massachusetts
1 Oct 2026Corporate CounselLegal, policy & complianceBoston, Massachusetts
25 Sep 2026Automation Scientist Graduate Intern, RAC OperationsResearch & scienceBoston, Massachusetts
17 Sep 2026Software Engineer III - Driver Developer (Autonomous Lab)Embedded & firmwareBoston, Massachusetts
2 Sep 2026Scientist, AI/ML — Antibody DevelopabilityML / AICalifornia, United States
25 Aug 2026Cheminformatics & Synthesis PredictionChip design (ASIC / RTL / verification / physical design)Boston, Massachusetts
24 Aug 2026Computational Synthetic ChemistResearch & scienceBoston, Massachusetts
21 Jul 2026Associate Director, Commercial Growth, ReagentsMarketing & communicationsBoston, Massachusetts

Reported lobbying spend: $120K in Q3 2026, $60K in Q2 2026. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.

DateChangeLobbying firmIssueSource
18 Nov 2025NewCrossroads Strategies, LLCfor Ginkgo Bioworks, Inc.Education and outreach on automated lab technology.MEDFiling
31 Dec 2024EndedKyle House Groupfor Ginkgo BioworksNot statedFiling
1 Jul 2023EndedHorizons Global Solutions LLCfor Ginkgo BioworksFY2024 NDAA; BiodefenseDefense, Health issuesFiling
21 May 2023EndedForbes-Tatefor Ginkgo BioworksIssues related to synthetic biology; Issues relate to critical minerals; Issues related to covid.; Issues related to synthetic biology; Issues related to critical minerals.; Issues related to bio-security; Issues related to critical minerals.; Issues related to synthetic biology.Health issues, Science/technology, Defense, AgricultureFiling
30 Apr 2023EndedGovernment Solutions LLCfor Ginkgo BioworksNot statedFiling
28 Mar 2023NewHorizons Global Solutions LLCfor Ginkgo Bioworks-FY24 National Defense Authorization Act -Department of Defense Biodefense Programs and PoliciesDefense, Health issuesFiling
1 Mar 2023NewCornerstone Government Affairs, Inc.for Perimeter Systems Inc, (Fka Ginkgo Bioworks, Inc.)Educate key government stakeholders on Ginkgo Bioworks medical detection and synthetic biology activities in support of the Department.Budget, Defense, MEDFiling
1 Mar 2023NewKyle House Groupfor Ginkgo BioworksEducation and advocacy in support of GinkgoFORFiling

Layoff notices

All 1 layoff notices

No notice in 12 months; the latest is dated 17 Jun 2024. State WARN notices.

NoticeSiteWorkersJobs endSource
17 Jun 2024Ginkgo Bioworks, Inc.Boston, Cambridge, MA15816 Aug 2024Notice

The 5 newest of 225 articles that name the company.

Timeline

Timeline

Changes and notable records, by the date each became public

  1. 16 Oct 2026Lobbying change

    reported $120K of lobbying spend for the quarter ended 30 Sep 2026, 4.0× its normal quarter.

    See the evidence
    This period
    $120K (the quarter ended 30 Sep 2026)
    Normal quarter (median of 7 earlier)
    $30K
    Typical spread (median absolute deviation)
    $10K
    How far from its usual level
    +4.5
    History used
    2,557 days
    2023-12-31: $40K2024-03-31: $30K2024-06-30: $30K2025-06-30: $10K2025-12-31: $30K2026-03-31: $60K2026-06-30: $60K2026-09-30: $120K
    the quarter ended 30 Sep 20267 earlier quartersnormal: $30K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least $100K.

    Check it at the source: Senate/House lobbying disclosures (LDA).

  2. 9 May 2026Government contracts record

    GINKGO BIOWORKS, INC.: new Department of Health and Human Services contract 75D30126F00004 ($3.2M) (dated 3 May 2026)

  3. 7 Apr 2026Filings record

    Completed an acquisition or asset sale

  4. 5 Apr 2026Government contracts change

    booked $21.0M in federal contract and grant obligations in March 2026, against none in the same month last year.

    See the evidence
    This period
    $21.0M (March 2026)
    Normal month (median of 4 earlier)
    $5K
    Typical spread (median absolute deviation)
    $5K
    How far from its usual level
    +21.0
    Same month last year
    $0
    History used
    1,566 days
    2022-03-01: $02023-03-01: $2.0M2024-03-01: $10K2025-03-01: $02026-03-01: $21.0M
    March 20264 earlier monthsnormal: $5K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 9+ earlier periods, 365+ days of history and a value of at least $5.0M.

    Check it at the source: USAspending.gov award search.

  5. 23 Dec 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  6. 23 Dec 2025Filings record

    Director or officer change

  7. 11 Dec 2025Lobbying record

    GINKGO BIOWORKS, INC.: new lobbying registration (CROSSROADS STRATEGIES, LLC) (dated 18 Nov 2025)

  8. 21 May 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  9. 21 May 2025Filings record

    Director or officer change

  10. 23 Jan 2025Government contracts change

    booked $54.2M in federal contract and grant obligations in January 2025, 2.8× the same month last year.

    Same month last year: $19.6M; its normal month is $672K.

    See the evidence
    This period
    $54.2M (January 2025)
    Normal month (median of 3 earlier)
    $672K
    Typical spread (median absolute deviation)
    $672K
    How far from its usual level
    +53.5
    Same month last year
    $19.6M
    History used
    1,142 days
    2022-01-01: $672K2023-01-01: $02024-01-01: $19.6M2025-01-01: $54.2M
    January 20253 earlier monthsnormal: $672K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 9+ earlier periods, 365+ days of history and a value of at least $5.0M.

    Check it at the source: USAspending.gov award search.

  11. 23 Jan 2025Government contracts record

    GINKGO BIOWORKS, INC.: new Department of Health and Human Services contract 75D30125C20439 ($53.7M) (dated 17 Jan 2025)

  12. 21 Jan 2025Lobbying record

    GINKGO BIOWORKS: lobbying engagement terminated (KYLE HOUSE GROUP) (dated 31 Dec 2024)

  13. 12 Nov 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  14. 12 Nov 2024Filings record

    Director or officer change

  15. 3 Oct 2024Government contracts change

    booked $10.2M in federal contract and grant obligations in September 2024, 5.8× the same month last year.

    Same month last year: $1.8M; its normal month is $887K.

    See the evidence
    This period
    $10.2M (September 2024)
    Normal month (median of 2 earlier)
    $887K
    Typical spread (median absolute deviation)
    $887K
    How far from its usual level
    +7.1
    Same month last year
    $1.8M
    History used
    1,019 days
    2022-09-01: $02023-09-01: $1.8M2024-09-01: $10.2M
    September 20242 earlier monthsnormal: $887K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 9+ earlier periods, 365+ days of history and a value of at least $5.0M.

    Check it at the source: USAspending.gov award search.

  16. 12 Sep 2024Government contracts record

    GINKGO BIOWORKS, INC.: new Department of Health and Human Services contract 75D30124F00001 ($1.2M) (dated 6 Sep 2024)

  17. 7 Sep 2024Government contracts change

    booked $54.5M in federal contract and grant obligations in August 2024, 3.4× the same month last year.

    Same month last year: $16.0M; its normal month is $16.0M.

    See the evidence
    This period
    $54.5M (August 2024)
    Normal month (median of 2 earlier)
    $16.0M
    Typical spread (median absolute deviation)
    $5K
    How far from its usual level
    +24.1
    Same month last year
    $16.0M
    History used
    989 days
    2022-08-01: $16.0M2023-08-01: $16.0M2024-08-01: $54.5M
    August 20242 earlier monthsnormal: $16.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 9+ earlier periods, 365+ days of history and a value of at least $5.0M.

    Check it at the source: USAspending.gov award search.

  18. 4 Sep 2024Filings record

    Delisting notice or listing transfer

  19. 1 Sep 2024Government contracts record

    GINKGO BIOWORKS, INC.: new Department of Health and Human Services contract 75D30124C19895 ($54.5M) (dated 26 Aug 2024)

  20. 18 Jun 2024Layoff notices change

    filed a WARN layoff notice covering 158 workers within 30 days (Boston, Cambridge, MA).

    See the evidence (1 source record)
    Notices in the window
    1
    Workers named
    158
    Window
    19 May 2024 to 18 Jun 2024

    Fires on a WARN notice after 30 days without one; notices within 30 days are summed.

  21. 18 Jun 2024Layoff notices record

    WARN notice: Ginkgo Bioworks, Inc., 158 workers, Boston, Cambridge, MA (dated 17 Jun 2024)

  22. 17 May 2024Insiders record

    Sankar Shyam (director) bought 625,000 shares of DNA ($512,500) (dated 16 May 2024)

  23. 15 May 2024Insiders record

    SLOAN HARRY (director) bought 297,619 shares of DNA ($270,833) (dated 14 May 2024)

  24. 13 May 2024Filings record

    Delisting notice or listing transfer

  25. 9 May 2024Filings record

    Restructuring costs announced

  26. 14 Mar 2024Filings record

    Changed its auditor

  27. 17 Jan 2024Government contracts change

    booked $19.0M in federal contract and grant obligations in January 2024, against none in the same month last year.

    See the evidence
    This period
    $19.0M (January 2024)
    Normal month (median of 2 earlier)
    $336K
    Typical spread (median absolute deviation)
    $336K
    How far from its usual level
    +18.6
    Same month last year
    $0
    History used
    776 days
    2022-01-01: $672K2023-01-01: $02024-01-01: $19.0M
    January 20242 earlier monthsnormal: $336K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 9+ earlier periods, 365+ days of history and a value of at least $5.0M.

    Check it at the source: USAspending.gov award search.

  28. 18 Oct 2023Lobbying record

    GINKGO BIOWORKS: lobbying engagement terminated (HORIZONS GLOBAL SOLUTIONS LLC) (dated 1 Jul 2023)

  29. 21 Aug 2023Lobbying change

    lobbying on a new issue.

    See the evidence
    New
    ['FOR']
    Rule
    only points whose every posting (and value revision) is at or before as_of
    Field
    issue_codes
    Metric
    lobbying.filings_count
    Point id
    12621247
  30. 21 Aug 2023Lobbying record

    GINKGO BIOWORKS: lobbying engagement terminated (GOVERNMENT SOLUTIONS LLC) (dated 30 Apr 2023)

  31. 16 Jul 2023Lobbying record

    GINKGO BIOWORKS: lobbying engagement terminated (FORBES-TATE) (dated 21 May 2023)

  32. 23 May 2023Insiders record

    Sankar Shyam (director) bought 400,000 shares of DNA ($512,000) (dated 22 May 2023)

  33. 23 May 2023Insiders record

    SLOAN HARRY (director) bought 350,000 shares of DNA ($448,000) (dated 22 May 2023)

  34. 5 May 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  35. 5 May 2023Filings record

    Director or officer change

  36. 21 Apr 2023Lobbying change

    reported $180K of lobbying spend for the quarter ended 31 Mar 2023, 2.0× the same quarter last year.

    Same quarter last year: $90K; its normal quarter is $90K.

    See the evidence
    This period
    $180K (the quarter ended 31 Mar 2023)
    Normal quarter (median of 8 earlier)
    $90K
    Typical spread (median absolute deviation)
    $0
    How far from its usual level
    +4.5
    Same quarter last year
    $90K
    History used
    1,278 days
    2021-03-31: $90K2021-06-30: $90K2021-09-30: $90K2021-12-31: $90K2022-03-31: $90K2022-06-30: $90K2022-09-30: $90K2022-12-31: $90K2023-03-31: $180K
    the quarter ended 31 Mar 20238 earlier quartersnormal: $90K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least $100K.

    Check it at the source: Senate/House lobbying disclosures (LDA).

  37. 14 Apr 2023Lobbying record

    GINKGO BIOWORKS: new lobbying registration (KYLE HOUSE GROUP) (dated 1 Mar 2023)

  38. 3 Apr 2023Lobbying record

    GINKGO BIOWORKS: new lobbying registration (HORIZONS GLOBAL SOLUTIONS LLC) (dated 28 Mar 2023)

  39. 17 Mar 2023Government contracts change

    won its first award from the Department of Defense, a $1.5M contract, after 1 earlier federal award from other agencies.

    See the evidence (1 source record)
    Source coverage starts
    7 Oct 2007
    Earlier events of other kinds
    1

    "First" means first in our data: it fires only when the source's history began at least 365 days earlier.

  40. 17 Mar 2023Government contracts record

    GINKGO BIOWORKS, INC.: new Department of Defense contract W911NF23C0002 ($1.5M) (dated 15 Dec 2022)

Showing the newest 40 of 78 entries; narrow the window or the kind of data to see older ones.

Not listed: 435 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001830214
Ticker
DNA
Domain
ginkgobioworks.com
Employer name
Ginkgo Bioworks, Inc. (1 unverified)
Hq location
MA|BOSTON|02210 (1 unverified)
Lobbying client
ginkgo bioworks, perimeter systems inc fka ginkgo bioworks
Name
Ginkgo Biosecurity, LLC, Ginkgo Bioworks Holdings, Inc., Ginkgo Bioworks, Inc, Ginkgo Bioworks Securities Corporation and 4 more
Uei
ED48JCA71333, V62PM6L4HV34
Wikidata
Q29026065
Wikipedia
Ginkgo Bioworks
  • DOL H-1B labor condition applications and PERM certifications5 data points27 Jul 2026 to 27 Jul 2026
  • Federal lobbying disclosures (LDA)10 records, 81 data points1 Jul 2019 to 30 Sep 2026
  • SEC Form 13F institutional holdings4 records, 189 data points30 Sep 2021 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)100 records23 Dec 2020 to 9 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)396 data points31 Dec 2018 to 30 Sep 2026
  • SEC Form 4 insider transactions370 records, 560 data points4 Oct 2022 to 21 Oct 2026
  • FINRA short interest (twice monthly)366 data points30 Sep 2021 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)2602 data points17 Sep 2021 to 20 Nov 2026
  • USASpending.gov federal awards6 records, 196 data points16 Dec 2021 to 28 Sep 2026
  • WARN layoff notices (state labor agencies)1 record, 3 data points17 Jun 2024 to 17 Jun 2024
  • Wikipedia pageviews2882 data points1 Jan 2019 to 21 Nov 2026